Tafenoquine

Tafenoquine
Identifiers
	IUPAC name N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl); phenoxy]quinolin-8-yl]pentane-1,4-diamine;
CAS Number	106635-80-7;
PubChem CID	115358;
CompTox Dashboard (EPA)	DTXSID90869466 ;
Chemical and physical data
Formula	C24H28F3N3O3
Molar mass	463.493 g/mol g·mol−1

Tafenoquine (also called WR-238605 or SB-252263) is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is currently being investigated as a potential treatment for malaria, as well as for malaria prevention.^[1]^[2]

The main advantage of tafenoquine is that it has a long half-life and therefore does not need to be taken as frequently as primaquine. Like primaquine, tafenoquine causes haemolysis in people with G-6-PD deficiency.^[1]

A shorter regimen has also been described as an advantage.^[3]

The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.^[4]

References

^ ^a ^b Shanks GD, Oloo AJ, Aleman GM; et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria" (^{[dead link]} – ^{Scholar search}). Clin Infect Dis. 33: 1968–74. doi:10.1086/324081. {{cite journal}}: Explicit use of et al. in: |author= (help); External link in |format= (help)CS1 maint: multiple names: authors list (link)
^ Lell B, Faucher JF, Missinou MA; et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study". Lancet. 355 (9220): 2041–5. doi:10.1016/S0140-6736(00)02352-7. PMID 10885356. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD (2008). "The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific". Transactions of the Royal Society of Tropical Medicine and Hygiene. 102 (11): 1095–101. doi:10.1016/j.trstmh.2008.04.024. PMID 18541280. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine". Trans R Soc Trop Med Hyg. 99 (1): 2–5. doi:10.1016/j.trstmh.2004.01.013.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[Shanks2001-1] Shanks GD, Oloo AJ, Aleman GM; et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria" (^{[dead link]} – ^{Scholar search}). Clin Infect Dis. 33: 1968–74. doi:10.1086/324081. {{cite journal}}: Explicit use of et al. in: |author= (help); External link in |format= (help)CS1 maint: multiple names: authors list (link)

[2] Lell B, Faucher JF, Missinou MA; et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study". Lancet. 355 (9220): 2041–5. doi:10.1016/S0140-6736(00)02352-7. PMID 10885356. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[pmid18541280-3] Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD (2008). "The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific". Transactions of the Royal Society of Tropical Medicine and Hygiene. 102 (11): 1095–101. doi:10.1016/j.trstmh.2008.04.024. PMID 18541280. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[4] Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine". Trans R Soc Trop Med Hyg. 99 (1): 2–5. doi:10.1016/j.trstmh.2004.01.013.

[1]

[2]

[3]

[4]